The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer

Heather A Wakelee; Chris H Takimoto; Arturo Lopez-Anaya; Quincy Chu; Gary Middleton; David Dunlop; Rodryg Ramlau; Natasha Leighl; Eric K Rowinsky; Desiree Hao; Petr Zatloukal; Charlotte D Jacobs; Jordi Rodon

doi:10.1007/s00280-011-1772-z

The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer

Heather A Wakelee, Chris H Takimoto, Arturo Lopez-Anaya, Quincy Chu, Gary Middleton, David Dunlop, Rodryg Ramlau, Natasha Leighl, Eric K Rowinsky, Desiree Hao, Petr Zatloukal, Charlotte D Jacobs, Jordi Rodon

Cancer and Genomic Sciences

Research output: Contribution to journal › Article › peer-review

13 Citations (Scopus)

Abstract

Bexarotene (Targretin(®) capsules) is a retinoid-X-receptor agonist and an inducer of CYP3A4-mediated metabolism. This phase I trial evaluated the pharmacokinetic (PK) and drug-drug interactions of bexarotene with chemotherapy and a lipid-lowering agent (atorvastatin or fenofibrate). This trial was run in parallel with phase III trials of the combinations to determine whether repeated doses of bexarotene capsules affect the pharmacokinetics (PK) of the chemotherapeutic or the lipid-lowering agents.

Original language	English
Pages (from-to)	563-71
Number of pages	9
Journal	Cancer Chemotherapy and Pharmacology
Volume	69
Issue number	2
DOIs	https://doi.org/10.1007/s00280-011-1772-z
Publication status	Published - 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00280-011-1772-z

Cite this

Wakelee, H. A., Takimoto, C. H., Lopez-Anaya, A., Chu, Q., Middleton, G., Dunlop, D., Ramlau, R., Leighl, N., Rowinsky, E. K., Hao, D., Zatloukal, P., Jacobs, C. D., & Rodon, J. (2012). The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 69(2), 563-71. https://doi.org/10.1007/s00280-011-1772-z

@article{f5758d0b09f44080937c06184d23b71e,

title = "The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer",

abstract = "Bexarotene (Targretin({\textregistered}) capsules) is a retinoid-X-receptor agonist and an inducer of CYP3A4-mediated metabolism. This phase I trial evaluated the pharmacokinetic (PK) and drug-drug interactions of bexarotene with chemotherapy and a lipid-lowering agent (atorvastatin or fenofibrate). This trial was run in parallel with phase III trials of the combinations to determine whether repeated doses of bexarotene capsules affect the pharmacokinetics (PK) of the chemotherapeutic or the lipid-lowering agents.",

author = "Wakelee, {Heather A} and Takimoto, {Chris H} and Arturo Lopez-Anaya and Quincy Chu and Gary Middleton and David Dunlop and Rodryg Ramlau and Natasha Leighl and Rowinsky, {Eric K} and Desiree Hao and Petr Zatloukal and Jacobs, {Charlotte D} and Jordi Rodon",

year = "2012",

doi = "10.1007/s00280-011-1772-z",

language = "English",

volume = "69",

pages = "563--71",

journal = "Cancer Chemotherapy and Pharmacology",

issn = "1432-0843",

publisher = "Springer",

number = "2",

}

Wakelee, HA, Takimoto, CH, Lopez-Anaya, A, Chu, Q, Middleton, G, Dunlop, D, Ramlau, R, Leighl, N, Rowinsky, EK, Hao, D, Zatloukal, P, Jacobs, CD & Rodon, J 2012, 'The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer', Cancer Chemotherapy and Pharmacology, vol. 69, no. 2, pp. 563-71. https://doi.org/10.1007/s00280-011-1772-z

The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer. / Wakelee, Heather A; Takimoto, Chris H; Lopez-Anaya, Arturo et al.
In: Cancer Chemotherapy and Pharmacology, Vol. 69, No. 2, 2012, p. 563-71.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - The effect of bexarotene on atorvastatin pharmacokinetics

T2 - results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer

AU - Wakelee, Heather A

AU - Takimoto, Chris H

AU - Lopez-Anaya, Arturo

AU - Chu, Quincy

AU - Middleton, Gary

AU - Dunlop, David

AU - Ramlau, Rodryg

AU - Leighl, Natasha

AU - Rowinsky, Eric K

AU - Hao, Desiree

AU - Zatloukal, Petr

AU - Jacobs, Charlotte D

AU - Rodon, Jordi

PY - 2012

Y1 - 2012

N2 - Bexarotene (Targretin(®) capsules) is a retinoid-X-receptor agonist and an inducer of CYP3A4-mediated metabolism. This phase I trial evaluated the pharmacokinetic (PK) and drug-drug interactions of bexarotene with chemotherapy and a lipid-lowering agent (atorvastatin or fenofibrate). This trial was run in parallel with phase III trials of the combinations to determine whether repeated doses of bexarotene capsules affect the pharmacokinetics (PK) of the chemotherapeutic or the lipid-lowering agents.

AB - Bexarotene (Targretin(®) capsules) is a retinoid-X-receptor agonist and an inducer of CYP3A4-mediated metabolism. This phase I trial evaluated the pharmacokinetic (PK) and drug-drug interactions of bexarotene with chemotherapy and a lipid-lowering agent (atorvastatin or fenofibrate). This trial was run in parallel with phase III trials of the combinations to determine whether repeated doses of bexarotene capsules affect the pharmacokinetics (PK) of the chemotherapeutic or the lipid-lowering agents.

U2 - 10.1007/s00280-011-1772-z

DO - 10.1007/s00280-011-1772-z

M3 - Article

C2 - 22057855

SN - 1432-0843

VL - 69

SP - 563

EP - 571

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

IS - 2

ER -

The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this